LSKL(a)

Research use only, not for human use.

LSKL Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide inhibits thrombospondin (TSP-1) activation of TGF-β.

LSKL Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide inhibits thrombospondin (TSP-1) activation of TGF-β.

The KTFR sequence from ADAMTS1 is responsible for the interaction with the LSKL, Inhibitor of Thrombospondin (TSP-1) (LSKL peptide) from the latent form of TGF-β, leading to its activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTFR sequence, characterized by 3 salt bridges and 2 hydrogen bonds.

LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling.LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL, Inhibitor of Thrombospondin (TSP-1) successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy. Animal Model:103 male Sprague-Dawley rats (6 weeks of age; 160-180 g) with subarachnoid hemorrhage (SAH) Dosage:1 mg/kg Administration:Intraperitoneal injection Result:Was protective against subarachnoid fibrosis, attenuated ventriculomegaly and effectively suppressed hydrocephalus.

——

Others

Other Targets

TGFβ

——

——

283609-79-0

458.6

C21H42N6O5

>98% (HPLC)

DMSO:100 mg/mL (218.05 mM)

CC(C)CC(N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(N)=O

——

(-20℃)

With Ice Pack

≥ 2 years